Please login to the form below

Not currently logged in
Email:
Password:

Inrebic

This page shows the latest Inrebic news and features for those working in and with pharma, biotech and healthcare.

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

It also comes on the heels of  another significant approval of Celgene’s JAK inhibitor Inrebic (fedratinib), which scored an FDA nod in August. ... Some analysts have predicted that Inrebic could also become a $1bn product in myelofibrosis, despite a

Latest news

  • Roche agrees $1.4bn takeover of fibrosis specialist Promedior Roche agrees $1.4bn takeover of fibrosis specialist Promedior

    anaemia. The only marketed therapies for myelofibrosis are currently Incyte/Novartis’ Jakafi (ruxolitinib), a $1.4bn JAK 1/2 inhibitor first approved in 2011, and Celgene’s newer JAK inhibitor  Inrebic ... Some analysts think Inrebic could become a

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    Currently in the middle of merger. After a turbulent development, Celgene has finally claimed FDA approval for Inrebic, its new drug for rare bone marrow disorder myelofibrosis. ... Inrebic (fedratinib) is the second JAK inhibitor to be approved for

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...